Skip to main content

Table 2 Comparison of clinical-laboratory characteristics between cluster group I and II patients with NPM1 mutated AML #

From: Hierarchical cluster analysis of immunophenotype classify AML patients with NPM1 gene mutation into two groups with distinct prognosis

 

Cluster group I (n = 82)

Cluster group II (n = 12)

P-Value

Age

  

1.000

 Adult(>18 years)

81

12

 

 Children

1

0

 

Gender

  

1.000

 Male

38

6

 

 Female

44

6

 

Laboratory data

   

 WBC(uL)

35710

43580

0.409

 Hemoglobin (g/dL)

8.5

8.5

0.710

 Platelet(uL)

49000

79000

<0.001

 LDH (units/L)

1056

1253

0.803

FAB subtype

  

0.173

 M0

0

0

 

 M1

17

0

 

 M2

26

7

 

 M3

0

0

 

 M4

28

5

 

 M5

10

0

 

 M6

1

0

 

 M7

0

0

 

 Undetermined

0

0

 

Cytogenetic

  

0.662

 Normal karyotype

67

10

 

 Abnormal karyotype

10

2

 

Associated gene mutation*

   

 FLT3-ITD

36(44)

10(83)

0.013

 FLT3-TKD

12(15)

1(8)

1.000

 NRAS

9(11)

3(25)

0.179

 KRAS

0

0

NA

 PTPN11

7(9)

0

0.589

 KIT

0

0

NA

 JAK2

0

0

NA

 MLL-PTD

0

0

NA

 WT1

2(2)

0

1.000

 CEBPA

4(4)

0

1.000

Immunophenotype**

   

 HLA-DR

34(41)

12(100)

<0.001

 CD7

3(4)

12(100)

<0.001

 CD13

76(93)

12(100)

1.000

 CD14

16(20)

2(17)

1.000

 CD15

36(47)

5(42)

1.000

 CD33

82(100)

12(100)

1.000

 CD34

9(11)

11(92)

<0.001

 CD56

19(23)

0

0.117

  1. Abbreviation: ITD, internal tandem duplication; TKD, tyrosine kinase domain mutation; PTD, partial tandem duplication; NA: not application.
  2. # Only 94 patients had complete immunophenotyping data and can be stratified by clustering analysis.
  3. * Number of patients (% of patients with this gene mutation in each cluster group).
  4. **Numbers of patients (% of patients with this antigen expression in each cluster group).
  5. All four patients with CEBPA mutation were mono-allelic.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us